APP and Alzheimer disease: This method was used to test for differential miRNA expression during early AD, and we assessed plasma samples from C57BL/6J controls (WT, male: n = 6, female: n = 6) and APP/PS1 mice (male: n = 6, female: n = 6) to verify significant differences between miR-34c-5p, miR-206-3p, miR-9-5p, miR-132-3p, miR-146a-5p, and miR-21-5p expression in the WT and AD groups.